Novan, Inc. (NOVN) News

Novan, Inc. (NOVN): $1.18

0.13 (+12.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NOVN News Items

NOVN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NOVN News Highlights

  • NOVN's 30 day story count now stands at 7.
  • Over the past 20 days, the trend for NOVN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DRUG, GEL and PRE are the most mentioned tickers in articles about NOVN.

Latest NOVN News From Around the Web

Below are the latest news stories about NOVAN INC that investors may wish to consider to help them evaluate NOVN as an investment opportunity.

Novan Announces Closing of $6.0 Million Registered Direct Offering

DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share

Yahoo | March 16, 2023

Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference

Presentation with live webcast today, March 14th at 10:40 AM ETDURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference today, March 14, 2023 at 10:40 AM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the

Yahoo | March 14, 2023

Novan Announces $6.0 Million Registered Direct Offering

DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per sh

Yahoo | March 14, 2023

3 Index Funds to Buy for March

Investors who want exposure to wide varieties of stocks should consider taking a position in one of these reputable index funds.

Joel Baglole on InvestorPlace | March 9, 2023

Novan Moves Forward with Unified Corporate Branding

– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified identity in advance of potential commercial launch of berdazimer gel, 10.3% (SB206) – DURHAM, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that its commercial subsidiary, EPI Health, will now unify under one brand name, Novan. “Since the

Yahoo | March 8, 2023

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024

– FDA completes filing review of application with no filing issues identified – – New Chemical Entity (“NCE”) has potential to be the first FDA-approved prescription product for molluscum in the U.S. – – Novan’s commercial team and sales force ready to prepare for launch of berdazimer gel, 10.3%, if approved – DURHAM, N.C., March 07, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that the U.S. Food and Drug Administration (“FDA”) accepted for fili

Yahoo | March 7, 2023

NOVN: NDA Submitted

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Mid Quarter Update Since reporting third quarter financial and operational results on November 14, 2022, Novan Inc. (NASDAQ:NOVN) has raised additional capital, entered into an exclusive licensing agreement with Sato Pharmaceutical and submitted its new drug application (NDA) to the FDA for SB206. Management also

Yahoo | March 2, 2023

Market Sentiment Around Loss-Making Novan, Inc. (NASDAQ:NOVN)

With the business potentially at an important milestone, we thought we'd take a closer look at Novan, Inc.'s...

Yahoo | February 24, 2023

Novan to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday, January 19th at 12:00 PM ETDURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 12:00 PM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (novan

Yahoo | January 18, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.

Yahoo | January 11, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8263 seconds.